CIK 0001649094 · Large accelerated filer
Vaxcyte, Inc.
Sign in to watch- Ticker
- PCVX
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 464233385
- Phone
- 650-837-0111
- Business address
- 825 INDUSTRIAL ROAD, STE. 300, SAN CARLOS, CA, 94070
- Former names
- SutroVax, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $5,185,988
- in 8 filings, $4.8M under 10b5-1 plans
Net −$5,185,988. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-07-18 | GUGGENHIME ANDREW PRESIDENT AND CFO | Option exercise 10b5-1 | +8,000 | $5.35 | $43K | 104,720 |
| 2024-07-18 | GUGGENHIME ANDREW PRESIDENT AND CFO | Sale 10b5-1 | −3,095 | $80.12 | $248K | 101,625 |
| 2024-07-18 | GUGGENHIME ANDREW PRESIDENT AND CFO | Sale 10b5-1 | −2,500 | $81.06 | $203K | 99,125 |
| 2024-07-18 | GUGGENHIME ANDREW PRESIDENT AND CFO | Sale 10b5-1 | −1,479 | $82.32 | $122K | 97,646 |
| 2024-07-18 | GUGGENHIME ANDREW PRESIDENT AND CFO | Sale 10b5-1 | −926 | $83.14 | $77K | 96,720 |
| 2024-07-18 | GUGGENHIME ANDREW PRESIDENT AND CFO | Option exercise · Stock Option (right to buy) 10b5-1 | −8,000 | 336,827 | ||
| 2024-07-16 | Cowan Elvia SVP, FINANCE | Option exercise 10b5-1 | +5,000 | $25.92 | $130K | 17,723 |
| 2024-07-16 | Cowan Elvia SVP, FINANCE | Sale 10b5-1 | −5,000 | $85.00 | $425K | 12,723 |
| 2024-07-16 | Cowan Elvia SVP, FINANCE | Option exercise · Stock Option (right to buy) 10b5-1 | −5,000 | 119,000 | ||
| 2024-07-08 | Cowan Elvia SVP, FINANCE | Option exercise 10b5-1 | +5,000 | $25.92 | $130K | 17,723 |
| 2024-07-08 | Cowan Elvia SVP, FINANCE | Sale 10b5-1 | −5,000 | $80.00 | $400K | 12,723 |
| 2024-07-08 | Cowan Elvia SVP, FINANCE | Option exercise · Stock Option (right to buy) 10b5-1 | −5,000 | 124,000 | ||
| 2024-07-02 | Furey John Director | Grant or award · Stock Option (right to buy) | +16,760 | 16,760 | ||
| 2024-07-01 | Eydelman Mikhail SVP, GEN COUNSEL & CORP SEC | Option exercise 10b5-1 | +1,667 | $21.41 | $36K | 32,493 |
| 2024-07-01 | Eydelman Mikhail SVP, GEN COUNSEL & CORP SEC | Sale 10b5-1 | −913 | $75.93 | $69K | 31,580 |
| 2024-07-01 | Eydelman Mikhail SVP, GEN COUNSEL & CORP SEC | Sale 10b5-1 | −754 | $76.90 | $58K | 30,826 |
| 2024-07-01 | Eydelman Mikhail SVP, GEN COUNSEL & CORP SEC | Option exercise · Stock Option (right to buy) 10b5-1 | −1,667 | 183,331 | ||
| 2024-07-01 | Wassil Jim CHIEF OPERATING OFFICER | Sale 10b5-1 | −1,226 | $75.75 | $93K | 212,277 |
| 2024-07-01 | Wassil Jim CHIEF OPERATING OFFICER | Sale 10b5-1 | −1,663 | $76.71 | $128K | 210,614 |
| 2024-07-01 | Wassil Jim CHIEF OPERATING OFFICER | Sale 10b5-1 | −111 | $77.22 | $9K | 210,503 |
Page 25 of 39 · 764 trades